RecruitingNot ApplicableNCT06523868

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Sponsor

Dana-Farber Cancer Institute

Enrollment

1,500 participants

Start Date

Mar 31, 2025

Study Type

INTERVENTIONAL

Conditions

Cancer Diagnosis

Summary

The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test

Eligibility

Min Age: 45 Years

Inclusion Criteria5

Active-duty or National Guard/Reserves military service for four or more years
Age ≥ 45
Received care at a VA facility within past 5 years
Able to sign informed consent
Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy

Exclusion Criteria3

Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable)
Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable)
Individuals in the process of being evaluated for a clinical suspicion of cancer

Interested in this trial?

Get notified about updates and connect with the research team.